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Abstract  30 
Background: Randomised controlled trials are considered the best method for determining the 31 
effectiveness and safety of health interventions. Trials involving children are essential to ensure that 32 
treatments are safe and effective. However, many trials, both adult and paediatric, do not achieve 33 
recruitment targets and/or maintain retention of participants, which can lead to a reduction in the 34 
internal and external validity of the results. Identifying ways of improving trial efficiency are important 35 
in order to increase the successful completion of trials.  36 
Main body: A  ‘Study Within A Trial ? (SWAT) is a self-contained study embedded within an ongoing 37 
trial, which aims to establish evidence to improve the management and delivery of trials in healthcare. 38 
There are increasing numbers of SWATs undertaken in recent years but very few within paediatric 39 
trials and here we describe some of the challenges with undertaking a programme of SWATs within 40 
paediatric clinical trials in the UK. The TRECA (TRials Engagement in Children and Adolescents) study 41 
involves developing multimedia websites to use within paediatric trials to provide recruitment 42 
information to children, young people and their families about the clinical trial. Challenges 43 
encountered included governance issues such as host trial approval processes and sharing of 44 
anonymised data; funding issues for host trials; internet quality and accessibility within the healthcare 45 
setting; and ethical concerns associated with SWAT methodology. We believe the ethical concerns are 46 
more pronounced in the paediatric setting, perhaps because fewer SWATs are undertaken there or 47 
that a more cautious, risk-averse approach to undertaking research with children is taken. 48 
Conclusion: SWATs are becoming increasingly common to provide an evidence base for methods for 49 
improving trial efficiency. However, we encountered a number of unanticipated challenges to 50 
embedding TRECA that have not been previously reported within the scientific literature. We believe 51 
that if these issues were addressed, through wider promotion and explanation of undertaking SWATs 52 
3 
involving all key stakeholders, as well as exploration of alternative funding models for SWATs, this 53 
would enable more streamlined, appropriate and timely processes for SWATs and enable a stronger 54 
evidence base for what works to increase trial efficiency. 55 
 56 
Trial registration: The TRECA study is registered on ISRCTN, ID 73136092. Registered on 24 August 57 
2016. 58 
 59 
Key words: ?Study Within A Trial ? (SWAT), embedded trials, methodology, challenges, randomised 60 
controlled trials, paediatrics, governance 61 
 62 
Background 63 
The need for evidence-informed trials 64 
Although randomised controlled trials (RCTs) are the gold standard for developing an evidence base 65 
on the effectiveness of healthcare interventions, significant uncertainties exist about their design, 66 
conduct and reporting, meaning that trials are often not efficient. For example, approximately 50% of 67 
trials fail to achieve their original recruitment targets [1]. Poor recruitment and retention of trial 68 
participants can be very costly [2] and contributes significantly to research waste [3, 4].  69 
 70 
The UK government has highlighted its ambition to accelerate the development of innovative 71 
medicines to improve patient health outcomes and healthcare efficiency [5]. However, without the 72 
ability to accelerate the evaluation of healthcare innovations, and for these evaluations to be 73 
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completed to time and to target, this ambition will be stymied. Despite our focus on the UK, this issue 74 
is faced by many health systems around the world. 75 
 76 
?Study within a Trial? (SWAT), an emerging field 77 
With the recognition that developing the evidence base for trials should be a priority, there has been a 78 
recent international movement to improve the efficiency and successful delivery of trials through the 79 
use of rigorous evaluation, adopting the  ‘Study Within A Trial ? (SWAT) methodology. A SWAT is a  ‘ƐĞůĨ-80 
contained study that has been embedded within a host trial with the aim of evaluating or exploring 81 
ĂůƚĞƌŶĂƚŝǀĞǁĂǇƐŽĨĚĞůŝǀĞƌŝŶŐŽƌŽƌŐĂŶŝƐŝŶŐĂƉĂƌƚŝĐƵůĂƌƚƌŝĂůƉƌŽĐĞƐƐ ?[6]. For instance, in the UK the 82 
Medical Research Council (MRC) funded the START (Systematic Techniques for Assisting Recruitment 83 
to Trials) programme that successfully developed a conceptual, methodological and logistical 84 
framework to improve recruitment through embedding SWATs of recruitment interventions in 85 
multiple host trials, and developed reporting guidelines for recruitment SWATs [7, 8]. The Northern 86 
Ireland Hub for Trials Methodology Research has established the SWAT Repository to facilitate SWATs 87 
[9]. Trial Forge is another UK initiative, based in Scotland, that aims to increase the evidence base for 88 
trial decision-making and in doing so, improve trial efficiency, and it recently published guidance for 89 
what is a SWAT [6]. The current MRC-funded PROMoting THE USE of SWATs (PROMETHEUS) 90 
programme [10] is building on the START initiative to make SWATs standard practice in clinical trials in 91 
the UK by funding and facilitating the start of at least 25 SWATs across multiple teams in the UK. 92 
Recently the UK National Institute for Health Research (NIHR) announced a new funding stream for 93 
 ‘^ƚƵĚŝĞƐtŝƚŚŝŶdƌŝĂů ?^tdƐ ? ?ŝŶƚŚĞ,ĞĂůƚŚdĞĐŚŶŽůŽŐǇƐƐĞƐƐŵĞŶƚ ?,d ?WƌŽŐƌĂmme [11], which 94 
has the potential to increase the number of trial teams likely to consider, and/or actively undertake 95 
SWATs. In the Republic of Ireland, the Health Research Board  W Trials Methodology Research Network 96 
(HRB-TMRN), support and fund research teams to undertake SWATs to improve the efficient conduct 97 
of future trials [12]. 98 
5 
Previously identified challenges with SWATs 99 
Despite the current focus on SWATs, a range of challenges to undertaking them have been identified. 100 
Challenges for host trials include increased complexity and management burden; compatibility 101 
between the host and embedded trials; and the impact of the embedded trial on host trial design and 102 
relationships with collaborators [13]. For embedded trials, there are concerns that host trial 103 
investigators might have strong preferences, limiting the control that embedded study investigators 104 
have over their research, and also concerns about sample size limiting statistical power [13]. Other 105 
identified challenges include cost; the resistance of the chief investigator or co-investigators; funding 106 
for SWATs; and distraction and additional workload for research staff [14, 15]. 107 
 108 
The TRECA Study, an example of a SWAT to evaluate a new recruitment intervention 109 
In this paper we discuss some of the challenges encountered within a programme of SWATs, the TRials 110 
Engagement in Children and Adolescents (TRECA) Study [16], funded by the UK NIHR Health Services 111 
and Delivery Research (HS&DR) Programme (14/21/21). TRECA is investigating a novel alternative to a 112 
printed participant information sheet (PIS) for children, young people and their parents, when 113 
approached about a clinical trial. This is an important opportunity to explore alternative methods of 114 
providing information as many PIS documents are lengthy, difficult to understand and do not 115 
incorporate visual elements [17-20]. In the first phase of the TRECA study, multimedia website 116 
templates about paediatric clinical trials using text, pictures, animations and short video clips were 117 
developed (unpublished data; J Martin-Kerry, P Knapp, K Atkin , P Bower, I Watt, C Stones, S Higgins, R 118 
Sheridan, J Preston, D Horton Taylor, B Young) and user tested [21]. Phase two of TRECA began in late 119 
2017 and involves adapting the multimedia websites for six paediatric clinical trials (host trials) using 120 
trial-specific content and embedding the websites as recruitment tools within the host trials. There is a 121 
lack of evidence on the effectiveness of multimedia for supporting decision-making about trials, 122 
particularly in the paediatric setting. When host trials embed TRECA, the trial randomises those 123 
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approached about trial participation to one of three arms of TRECA so that each person approached 124 
receives one of the following: the PIS only; the multimedia website only; or both the PIS and 125 
multimedia website. We are interested in the impact of the multimedia websites on rates of 126 
recruitment and retention to the six trials, as well as the quality of decision-making by families about 127 
trial participation. 128 
 129 
Despite much interest and enthusiasm for SWATs, and clear benefits for utilising them to evaluate 130 
new methodological interventions within RCTs [6], we have encountered a number of challenges to 131 
embedding TRECA within UK paediatric trials. Here we describe these challenges and suggest some 132 
possible solutions that may enable SWATs to be undertaken more quickly and efficiently within a 133 
pediatric context, or other settings where there is a perception of patient vulnerability or risk. 134 
 135 
Challenges faced by TRECA 136 
The main challenges encountered when engaging with potential host trials to embed TRECA fall under 137 
four main categories: governance and approvals; funding; methodological/ethical concerns; and 138 
internet access and quality. 139 
 140 
Governance and approvals issues 141 
A number of governance and approvals issues have been encountered when embedding TRECA within 142 
host paediatric trials: 143 
 144 
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Within Phase two of TRECA, each of the six host trials had different approval processes to embed 145 
TRECA. Some trials required their Trial Management Group (TMG) to formally approve collaboration. 146 
Other host trials requested that a feasibility questionnaire be developed by TRECA and sent to all 147 
potential host trial sites. The questionnaires were accompanied by information about TRECA in terms 148 
of the practicalities of what would be involved if the host trial site was to embed TRECA. We sought 149 
ĞĂĐŚƐŝƚĞ ?ƐĂƉƉƌŽǀĂůĂŶĚĂŐƌĞĞŵĞŶƚǁŝƚŚĞŵďĞĚĚŝŶŐdZ through the completion of a set of 150 
questions relating to the process of embedding TRECA. From this, the decision still rested with the 151 
TMG which may have only met infrequently. One host trial required two sets of feasibility 152 
questionnaires to be circulated to the trial sites  W one prior to a decision by the host TMG about 153 
embedding TRECA, and another following this decision. In our experience it has often taken three to 154 
eight months from initial discussions with the potential host trial until the trial has made a decision 155 
about embedding TRECA. This has had an important time-delaying impact on TRECA ?Ɛtimelines. 156 
Crucially, TRECA could not begin developing the multimedia websites (given they are tailored to the 157 
trial) until the decision was made by the host trial, and the delay then impacted on the development 158 
and embedding of the websites (the tested recruitment intervention). 159 
 160 
So that TRECA could evaluate the impact of the multimedia websites on recruitment, retention and 161 
quality of decision-making, we require anonymised patient data from each host trial. To this end, we 162 
developed a data sharing agreement. Whilst we expected that these agreements would be 163 
straightforward, host trial sponsors have raised concerns about sharing even anonymised data, and 164 
legal teams from the ŚŽƐƚƚƌŝĂůƐ ?sponsors have reviewed and queried the agreements prior to signing. 165 
In addition, recent changes in data protection with the recent General Data Protection Regulation and 166 
Data Protection Act 2018 have also led to further concerns about sharing of anonymised data, and the 167 
need for a transparent approach to informing participants about the sharing of their data between 168 
organisations. One host trial noted that the sponsor of the host trial would not be signing the 169 
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agreement, and instead required each participating host trial site to sign an individual data sharing 170 
agreement with TRECA, increasing the administration and workload substantially. 171 
 172 
Funding issues for trials embedding SWATs 173 
Another challenge encountered relates to funding. The NIHR Clinical Research Network (CRN) provide 174 
funding to trials in the UK through the process of funding per participant recruited (accruals) for so-175 
ĐĂůůĞĚ ‘portfolio-adopted ? research studies. The Portfolio comprises high quality clinical research 176 
studies that are eligible for CRN funding and support. Recruitment data allows the allocation of 177 
funding to the NIHR Local Clinical Research Networks (LCRNs) to direct NHS service support to sites. 178 
Almost every trial we have approached about TRECA has asked or assumed that the host trial would 179 
receive two sets of accruals  W one for recruitment of their participants into the host trial, and the 180 
second for those who were randomised to TRECA. However, the CRN considers this situation to be 181 
 ‘double-counting ? as all of those recruited to the host trial would have been approached using one of 182 
the arms of TRECA and an additional consent process for the SWAT is not required. However, we can 183 
ƐĞĞƚŚĞƚƌŝĂů ?ƐǀŝĞǁƚŚĂƚďǇĞŵďĞĚĚŝŶŐdZƚŚĞǇĂƌĞŝŶƚƌŽĚƵĐŝŶŐŵŽƌĞǁŽrkload, although the 184 
TRECA team aims to reduce this burden as much as is practicable. Receiving additional funding for the 185 
local CRN may provide an incentive for a trial to embed a SWAT, particularly for the recruiters, as this 186 
funding may enable the CRN to support the trial team.  187 
 188 
Another accrual issue relates to a potential host trial for TRECA that was not portfolio-adopted. This 189 
particular host trial team thought that by embedding TRECA, which is an NIHR portfolio-adopted 190 
study, they would then be able to access an NIHR research nurse through funding/accruals to 191 
undertake recruitment for the host trial. However, under the current CRN process this was not 192 
possible. This raises the question of whether another funding model would assist with recruiting trials 193 
to undertake SWATs. A middle ground may be to provide a recruitment incentive for trials to 194 
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undertake SWATs but below the level of accrual/funding for recruiting a trial participant. Another 195 
option is to utilise the PROMETHEUS [10] model 196 
(https://www.york.ac.uk/healthsciences/research/trials/research/swats/prometheus/) with a flat rate 197 
for a SWAT provided to the trial team.  198 
 199 
Confusion around embedded trial methodology and ethical concerns 200 
Trialists have often been unsure about the methodology and approvals of embedded trials. We sought 201 
overarching research ethics and Health Research Authority (HRA) approvals for TRECA prior to 202 
identifying and approaching potential host trials. In this overarching ethics application we sought (and 203 
received) approval so that host trials do not need to explain TRECA or seek consent for those 204 
approached about the host trial in order to be randomised within TRECA. This is because explaining 205 
TRECA to those approached about the host trial and seeking consent to TRECA would be confusing and 206 
may also confound the effect of the information intervention being tested in the SWAT. However, 207 
trials have generally expressed concern about people not needing to consent to the embedded trial, 208 
despite these concerns not being raised by research ethics committees or the HRA.  209 
 210 
In addition, NHS Trust Research & Development (R&D) departments (these departments are located 211 
within NHS sites and are responsible for granting approval for research studies being undertaken 212 
locally) are often unclear of how to review and approve embedded trials, which causes delays. For 213 
example, one trial initially reviewed the TRECA documentation as an embedded study and then 214 
decided that TRECA would be reviewed as a stand-alone study and requested all documentation to be 215 
sent again and reviewed. In addition, R&D departments were often unsure about which 216 
documentation they needed to review and some had concerns about participants not consenting to 217 
the SWAT (despite ethics approval for this process). These additional steps caused further delays in 218 
embedding TRECA. 219 
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 220 
Accessibility and quality of internet provision 221 
An unexpected challenge with undertaking a SWAT involving the delivery of a multimedia website 222 
within the healthcare setting was the variation in wifi conditions and permissions at each National 223 
Health Service (NHS) site. This proved challenging when developing the multimedia websites for host 224 
trials as the Principal Investigator for one host trial was unable to view the websites due to internet 225 
viewing restrictions at the hospital (the videos and animations are stored on a site which was blocked 226 
at this particular hospital). Furthermore, some wifi was either too slow to load animations and videos 227 
or could not be reliably accessed. We overcame this issue by providing affected sites with a tablet 228 
computer that had an internet SIM card. 229 
 230 
Other learnings from the TRECA study 231 
Despite the challenges we faced with incorporating this programme of SWATs within six host trials, we 232 
have encountered a number of positive experiences. There is a genuine interest in presenting 233 
information about trials to families in a more engaging way and there has been a great deal of 234 
enthusiasm for the multimedia websites created. We have also found RECs and the HRA to be very 235 
supportive of us evaluating the use of multimedia websites as an alternative or supplement to printed 236 
PIS documents. We have also developed a structured and quality method of creating multimedia 237 
websites by working with host trials and a company that specializes in developing websites and 238 
animation (Morph; www.morph.co.uk). For researchers wanting to implement SWATs in future, we 239 
would recommend early engagement with all stakeholders (including trialists, sponsors, R&D 240 
department staff) about incorporating a SWAT so that any concerns or queries are addressed early. 241 
We would also factor in a lead time of six months for trials to sign the data sharing agreement. 242 
 243 
11 
Conclusions 244 
SWATs have become increasingly popular, offering an opportunity to identify what works best when 245 
undertaking trials [6]. In conducting Phase two of the TRECA study, we have identified and described a 246 
number of governance, funding and methodological challenges when embedding a programme of 247 
SWATs within host paediatric trials. There are a small number of publications describing challenges 248 
with embedding SWATs [13-15]; however, some of the issues identified within the TRECA study have 249 
not previously been described and this paper provides detailed information about the challenges 250 
faced. We also are not aware of any publications about SWATs undertaken within paediatric trials, and 251 
believe that some of the challenges we have experienced have a more marked impact in the paediatric 252 
context and in other contexts where there is a perception of increased patient vulnerability or risk. For 253 
example, a recent Cochrane review showed that only one of 68 trials evaluating strategies to improve 254 
recruitment into RCTs had included a paediatric sample [22]. However, we believe that the challenges 255 
we have identified within TRECA may be applicable to trials with other populations including trials 256 
involving adults and are relevant for other researchers wishing to undertake SWATs in a variety of 257 
trials and settings. We also acknowledge that the issue of internet quality and access will only impact 258 
on SWATs that involve delivery of websites and not on other methods of information provision. 259 
 260 
We believe that the identified challenges are able to be overcome, enabling a more streamlined and 261 
proportionate approach to trials reviewing requests for SWATs. We suggest that increasing awareness 262 
of SWATs more widely in the UK, such as through publications and presentations, and ensuring that 263 
paediatric trialists are involved, would assist with some of the ethical concerns raised, such as 264 
participants not needing to provide explicit consent for the SWAT. We feel that the ethical concerns 265 
expressed by host trials for TRECA reflect that this study was undertaken in the paediatric setting 266 
where there may be more caution about novel methods. It is important that all stakeholders are 267 
involved in a process of increasing SWATs awareness, including members of ethical committees, 268 
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sponsor representatives, principal investigators, trial managers and coordinators, TMGs, CRN, R&D 269 
officers, trial managers and coordinators at trial sites and clinical trial units.  270 
 271 
We also feel that the provision of more guidance to NHS sites and trials about how to review a SWAT, 272 
and identifying earlier whether the host trial is able to embed it, would be beneficial. Undertaking 273 
feasibility with sites participating in a multi-centre trial takes considerable time to develop and 274 
distribute the questionnaire, answer site queries, collate results and then await TMG review. In 275 
addition, we have found that a number of R&D departments have not been familiar with SWAT 276 
methods, how to review SWATs, or the order in which they should review and approve studies (i.e. 277 
approval before or after the host trial). R&D departments ultimately approve the undertaking of 278 
SWATs at sites and are often not involved in early discussions with trialists about including a SWAT. 279 
Ensuring that R&D departments are more familiar with SWATs would streamline the process of 280 
incorporation within new and existing trials. If these elements can be addressed, we would hope that 281 
this would enable more SWATs to be undertaken, providing a stronger evidence base about what 282 
works best in RCTs. In terms of funding models for host trials embedding a SWAT, we feel alternative 283 
models should be explored to generate incentives for host trials that match the workload of 284 
undertaking the SWAT, and the HTA funding stream may provide a viable funding alternative. We have 285 
described the UK situation but feel that these issues of funding support to host trials may be similar in 286 
other countries. 287 
 288 
In summary, we suggest that the following actions may overcome some of the challenges with 289 
undertaking SWATs in the paediatric setting: 290 
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1. Reduce ethical approval and governance barriers by increasing awareness of SWATs and engaging 291 
all stakeholders (including ethical committees, sponsor representatives, principal investigators, trial 292 
managers and coordinators, TMGs, R&D and trial sites). 293 
2. Provide more guidance and explanation about SWATs. In the UK, this could be led by NIHR or HRA, 294 
who are perhaps best positioned to provide the guidance and support. 295 
3. Explore other funding models that may better support SWATs. This may be through a down-296 
weighted recruitment incentive for SWATs through the CRN, or using the PROMETHEUS model of 297 
providing a set amount to trial teams for undertaking a SWAT, or using the new HTA funding stream.  298 
4. Review existing internet access in hospitals to determine whether improved access can be enabled 299 
to allow interventions such as multimedia websites about trials or healthcare treatments to be 300 
accessed more easily. 301 
 302 
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